Clinical Trial Update: Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

View source ↗

Summary

This clinical trial update describes a study evaluating early rebiopsy to identify biomarkers of tumor cell survival after EGFR, ALK, ROS1, or BRAF tyrosine kin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University of Colorado, Denver | Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer | Status: RECRUITING